Similar Search Results

Big pharma and monopoly capitalism: a long-term view

Dosi, Giovanni; Marengo, Luigi; Staccioli, Jacopo; … - 2021

Are IPRs institutions meant to foster innovative activities or conversely to secure appropriation and profitability? Taking stock of a long-term empirical evidence on the pharmaceutical sector in the US, we can hardly support IPRs intended as an innovation rewarding institution. According to our...

Persistent link: https://www.econbiz.de/10012604733

Access to medicines after TRIPS : is compulsory licensing an effective mechanism to lower drug prices? ; a review of the existing evidence

Urias, Eduardo; Ramani, Shyama V. - In: Journal of International Business Policy : JIBP 3 (2020) 4, pp. 367-384

Persistent link: https://www.econbiz.de/10012405471

The impact of patent protection on US pharmaceutical exports to developing countries

Boring, Anne - In: Applied economics 47 (2015) 13/15, pp. 1314-1330

Persistent link: https://www.econbiz.de/10010512063

Balancing the right to know and the privacy of the patent system : a case study on oncology medicines in Thailand

Yamabhai, Inthira; Smith, Richard - In: International journal of intellectual property … 6 (2013) 4, pp. 272-284

Persistent link: https://www.econbiz.de/10010252982

The effect of intellectual property rights on domestic innovation in the pharmaceutical sector

Gamba, Simona - 2016

This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of 74 countries. The identification strategy exploits the different timing across countries of two sets of IPR reforms. Domestic innovation is measured as citation-weighted...

Persistent link: https://www.econbiz.de/10011509446

The effect of intellectual property rights on domestic innovation in the pharmaceutical sector

Gamba, Simona - In: World development : the multi-disciplinary … 99 (2017), pp. 15-27

Persistent link: https://www.econbiz.de/10011925529

Product patents and access to innovative medicines in a post-trips-era

Watal, Jayashree; Dai, Rong - 2019 - Manuscript date: 28 March 2019

This WTO working paper studies availability and affordability of new and innovative pharmaceuticals in a post-TRIPS era …. The WTO's TRIPS Agreement (TRIPS) makes it obligatory for WTO members − except least-developed country members (LDCs) - to … to be compliant with this provision of TRIPS by 2005. This study investigates two questions in this context: (1) How does …

Persistent link: https://www.econbiz.de/10011992779

Efficiency evaluation of selected Indian pharmaceutical firms since inception of product patent

Bhattacharyya, Sucharita; Chatterjee, Susmita - In: International journal of management concepts and … 13 (2020) 4, pp. 292-318

Persistent link: https://www.econbiz.de/10012514629

Recognizing public goods in WTO dispute settlement : who participates? Who decides? The case of TRIPS and pharmaceutical patent protection

Shaffer, Gregory C. - In: International public goods and transfer of technology …, (pp. 884-908). 2005

Persistent link: https://www.econbiz.de/10003415336

Expanding patent rights in pharmaceuticals : the linkage between patents and drug registration

Correa, Carlos María - In: The development agenda : global intellectual property …, (pp. 247-263). 2009

Persistent link: https://www.econbiz.de/10003910927